Lexaria Bioscience Corp (NASDAQ:LEXX) shares, rose in value on Thursday, April 16, with the stock price down by -1.43% to the previous day’s close as strong demand from buyers drove the stock to $1.38.
Actively observing the price movement in the last trading, the stock closed the session at $1.40, falling within a range of $1.3405 and $1.4753. The value of beta (5-year monthly) was 0.852. Referring to stock’s 52-week performance, its high was $4.44, and the low was $1.15. On the whole, LEXX has fluctuated by -4.17% over the past month.
With the market capitalization of Lexaria Bioscience Corp currently standing at about $24.23 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LEXX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LEXX currently trading nearly -11.02% and -8.77% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.36, while the 7-day volatility ratio is showing 8.28% which for the 30-day chart, stands at 9.46%. Furthermore, Lexaria Bioscience Corp (LEXX)’s beta value is 1.02, and its average true range (ATR) is 0.14.
A comparison of Lexaria Bioscience Corp (LEXX) with its peers suggests the former has fared considerably weaker in the market. LEXX showed an intraday change of -1.43% in last session, and over the past year, it shrunk by -40.26%%.
Data on historical trading for Lexaria Bioscience Corp (NASDAQ:LEXX) indicates that the trading volumes over the past 10 days have averaged 54760.0 and over the past 3 months, they’ve averaged 100.63K. According to company’s latest data on outstanding shares, there are 17.45 million shares outstanding.
Nearly 7.31% of Lexaria Bioscience Corp’s shares belong to company insiders and institutional investors own 8.31% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.68 million shares as on 2025-03-31, resulting in a short ratio of 5.77. According to the data, the short interest in Lexaria Bioscience Corp (LEXX) stood at 436.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 0.55 million. The stock has fallen by -34.29% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LEXX stock heading into the next quarter.
